Unclassified renal cell carcinoma: a report of 56 cases

Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Unclassified RCC represents 0.7–5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases ar...

Full description

Saved in:
Bibliographic Details
Published inBJU international Vol. 110; no. 6; pp. 786 - 793
Main Authors Lopez‐Beltran, Antonio, Kirkali, Ziya, Montironi, Rodolfo, Blanca, Ana, Algaba, Ferran, Scarpelli, Marina, Yorukoglu, Kutsal, Hartmann, Arndt, Cheng, Liang
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.09.2012
Wiley-Blackwell
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1464-4096
1464-410X
1464-410X
DOI10.1111/j.1464-410X.2012.10934.x

Cover

Abstract Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Unclassified RCC represents 0.7–5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases are at an advanced stage at presentation, but overall and cancer‐specific survival were not significantly different between unclassified and clear‐cell RCC in an additional series of 38 patients. Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 WHO histotype are independent predictors of disease‐free and cancer‐specific survival. OBJECTIVE •  To evaluate the clinicopathological features and outcomes of 56 patients with unclassified renal cell carcinoma (RCC) meeting 2004 World Health Organization diagnostic criteria. PATIENTS AND METHODS •  Urological pathology files of the participating institutions were reviewed and cases of unclassified RCC that met the inclusion criteria were retrieved. •  Nuclear grade, pT status, tumour size, regional lymph node involvement, distant metastases, coagulative tumour necrosis, mucin and sarcomatoid differentiation were evaluated in radical nephrectomy or nephron‐sparing specimens. •  Significant factors in univariate analysis were then assessed by a multivariate analysis of independent prognostic factors using Cox proportional hazard regression analysis. RESULTS •  Fifty‐six cases met the histological criteria for unclassified RCC. Thirty‐four (61%) cases were categorized as unrecognizable cell type (mean overall survival 47 months; median 36 months), 20 (36%) as composites of recognized types (mean overall survival 36 months; median 26 months), and two (4%) (mean survival 16 months; median 16 months) as pure sarcomatoid morphology without recognizable epithelial elements. •  Cox multivariate analysis showed nuclear grade (P= 0.020), stage (P < 0.001), tumour coagulative necrosis (P= 0.018), tumour size (P < 0.001), microvascular invasion (P < 0.001) and tumour histotype (P= 0.028) to be independent predictors of disease‐free survival, with tumour size being the most significant (hazard ratio [HR] 9.068, 95% confidence interval [CI] 3.231–25.453). •  Nuclear grade (P= 0.026), stage (P < 0.001), tumour coagulative necrosis (P < 0.001), tumour size (P= 0.044), microvascular invasion (P < 0.001), tumour recurrence after surgery (P < 0.001) and tumour histotype (P= 0.056) were independent predictors of cancer‐specific survival, with tumour recurrence after surgery being the most significant (HR 14.713, 95% CI 5.329–40.622). CONCLUSION •  The prognosis of patients with unclassified RCC seems to be related to clinicopathological features known to be relevant in common forms of RCC.
AbstractList What's known on the subject? and What does the study add? Unclassified RCC represents 0.7-5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases are at an advanced stage at presentation, but overall and cancer-specific survival were not significantly different between unclassified and clear-cell RCC in an additional series of 38 patients. Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 WHO histotype are independent predictors of disease-free and cancer-specific survival. To evaluate the clinicopathological features and outcomes of 56 patients with unclassified renal cell carcinoma (RCC) meeting 2004 World Health Organization diagnostic criteria. Urological pathology files of the participating institutions were reviewed and cases of unclassified RCC that met the inclusion criteria were retrieved. Nuclear grade, pT status, tumour size, regional lymph node involvement, distant metastases, coagulative tumour necrosis, mucin and sarcomatoid differentiation were evaluated in radical nephrectomy or nephron-sparing specimens. Significant factors in univariate analysis were then assessed by a multivariate analysis of independent prognostic factors using Cox proportional hazard regression analysis. Fifty-six cases met the histological criteria for unclassified RCC. Thirty-four (61%) cases were categorized as unrecognizable cell type (mean overall survival 47 months; median 36 months), 20 (36%) as composites of recognized types (mean overall survival 36 months; median 26 months), and two (4%) (mean survival 16 months; median 16 months) as pure sarcomatoid morphology without recognizable epithelial elements. Cox multivariate analysis showed nuclear grade (P = 0.020), stage (P < 0.001), tumour coagulative necrosis (P = 0.018), tumour size (P < 0.001), microvascular invasion (P < 0.001) and tumour histotype (P = 0.028) to be independent predictors of disease-free survival, with tumour size being the most significant (hazard ratio [HR] 9.068, 95% confidence interval [CI] 3.231-25.453). Nuclear grade (P = 0.026), stage (P < 0.001), tumour coagulative necrosis (P < 0.001), tumour size (P = 0.044), microvascular invasion (P < 0.001), tumour recurrence after surgery (P < 0.001) and tumour histotype (P = 0.056) were independent predictors of cancer-specific survival, with tumour recurrence after surgery being the most significant (HR 14.713, 95% CI 5.329-40.622). The prognosis of patients with unclassified RCC seems to be related to clinicopathological features known to be relevant in common forms of RCC.
What's known on the subject? and What does the study add? Unclassified RCC represents 0.7-5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases are at an advanced stage at presentation, but overall and cancer-specific survival were not significantly different between unclassified and clear-cell RCC in an additional series of 38 patients. Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 WHO histotype are independent predictors of disease-free and cancer-specific survival.UNLABELLEDWhat's known on the subject? and What does the study add? Unclassified RCC represents 0.7-5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases are at an advanced stage at presentation, but overall and cancer-specific survival were not significantly different between unclassified and clear-cell RCC in an additional series of 38 patients. Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 WHO histotype are independent predictors of disease-free and cancer-specific survival.To evaluate the clinicopathological features and outcomes of 56 patients with unclassified renal cell carcinoma (RCC) meeting 2004 World Health Organization diagnostic criteria.OBJECTIVETo evaluate the clinicopathological features and outcomes of 56 patients with unclassified renal cell carcinoma (RCC) meeting 2004 World Health Organization diagnostic criteria.Urological pathology files of the participating institutions were reviewed and cases of unclassified RCC that met the inclusion criteria were retrieved. Nuclear grade, pT status, tumour size, regional lymph node involvement, distant metastases, coagulative tumour necrosis, mucin and sarcomatoid differentiation were evaluated in radical nephrectomy or nephron-sparing specimens. Significant factors in univariate analysis were then assessed by a multivariate analysis of independent prognostic factors using Cox proportional hazard regression analysis.PATIENTS AND METHODSUrological pathology files of the participating institutions were reviewed and cases of unclassified RCC that met the inclusion criteria were retrieved. Nuclear grade, pT status, tumour size, regional lymph node involvement, distant metastases, coagulative tumour necrosis, mucin and sarcomatoid differentiation were evaluated in radical nephrectomy or nephron-sparing specimens. Significant factors in univariate analysis were then assessed by a multivariate analysis of independent prognostic factors using Cox proportional hazard regression analysis.Fifty-six cases met the histological criteria for unclassified RCC. Thirty-four (61%) cases were categorized as unrecognizable cell type (mean overall survival 47 months; median 36 months), 20 (36%) as composites of recognized types (mean overall survival 36 months; median 26 months), and two (4%) (mean survival 16 months; median 16 months) as pure sarcomatoid morphology without recognizable epithelial elements. Cox multivariate analysis showed nuclear grade (P = 0.020), stage (P < 0.001), tumour coagulative necrosis (P = 0.018), tumour size (P < 0.001), microvascular invasion (P < 0.001) and tumour histotype (P = 0.028) to be independent predictors of disease-free survival, with tumour size being the most significant (hazard ratio [HR] 9.068, 95% confidence interval [CI] 3.231-25.453). Nuclear grade (P = 0.026), stage (P < 0.001), tumour coagulative necrosis (P < 0.001), tumour size (P = 0.044), microvascular invasion (P < 0.001), tumour recurrence after surgery (P < 0.001) and tumour histotype (P = 0.056) were independent predictors of cancer-specific survival, with tumour recurrence after surgery being the most significant (HR 14.713, 95% CI 5.329-40.622).RESULTSFifty-six cases met the histological criteria for unclassified RCC. Thirty-four (61%) cases were categorized as unrecognizable cell type (mean overall survival 47 months; median 36 months), 20 (36%) as composites of recognized types (mean overall survival 36 months; median 26 months), and two (4%) (mean survival 16 months; median 16 months) as pure sarcomatoid morphology without recognizable epithelial elements. Cox multivariate analysis showed nuclear grade (P = 0.020), stage (P < 0.001), tumour coagulative necrosis (P = 0.018), tumour size (P < 0.001), microvascular invasion (P < 0.001) and tumour histotype (P = 0.028) to be independent predictors of disease-free survival, with tumour size being the most significant (hazard ratio [HR] 9.068, 95% confidence interval [CI] 3.231-25.453). Nuclear grade (P = 0.026), stage (P < 0.001), tumour coagulative necrosis (P < 0.001), tumour size (P = 0.044), microvascular invasion (P < 0.001), tumour recurrence after surgery (P < 0.001) and tumour histotype (P = 0.056) were independent predictors of cancer-specific survival, with tumour recurrence after surgery being the most significant (HR 14.713, 95% CI 5.329-40.622).The prognosis of patients with unclassified RCC seems to be related to clinicopathological features known to be relevant in common forms of RCC.CONCLUSIONThe prognosis of patients with unclassified RCC seems to be related to clinicopathological features known to be relevant in common forms of RCC.
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Unclassified RCC represents 0.7–5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases are at an advanced stage at presentation, but overall and cancer‐specific survival were not significantly different between unclassified and clear‐cell RCC in an additional series of 38 patients. Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 WHO histotype are independent predictors of disease‐free and cancer‐specific survival. OBJECTIVE •  To evaluate the clinicopathological features and outcomes of 56 patients with unclassified renal cell carcinoma (RCC) meeting 2004 World Health Organization diagnostic criteria. PATIENTS AND METHODS •  Urological pathology files of the participating institutions were reviewed and cases of unclassified RCC that met the inclusion criteria were retrieved. •  Nuclear grade, pT status, tumour size, regional lymph node involvement, distant metastases, coagulative tumour necrosis, mucin and sarcomatoid differentiation were evaluated in radical nephrectomy or nephron‐sparing specimens. •  Significant factors in univariate analysis were then assessed by a multivariate analysis of independent prognostic factors using Cox proportional hazard regression analysis. RESULTS •  Fifty‐six cases met the histological criteria for unclassified RCC. Thirty‐four (61%) cases were categorized as unrecognizable cell type (mean overall survival 47 months; median 36 months), 20 (36%) as composites of recognized types (mean overall survival 36 months; median 26 months), and two (4%) (mean survival 16 months; median 16 months) as pure sarcomatoid morphology without recognizable epithelial elements. •  Cox multivariate analysis showed nuclear grade (P= 0.020), stage (P < 0.001), tumour coagulative necrosis (P= 0.018), tumour size (P < 0.001), microvascular invasion (P < 0.001) and tumour histotype (P= 0.028) to be independent predictors of disease‐free survival, with tumour size being the most significant (hazard ratio [HR] 9.068, 95% confidence interval [CI] 3.231–25.453). •  Nuclear grade (P= 0.026), stage (P < 0.001), tumour coagulative necrosis (P < 0.001), tumour size (P= 0.044), microvascular invasion (P < 0.001), tumour recurrence after surgery (P < 0.001) and tumour histotype (P= 0.056) were independent predictors of cancer‐specific survival, with tumour recurrence after surgery being the most significant (HR 14.713, 95% CI 5.329–40.622). CONCLUSION •  The prognosis of patients with unclassified RCC seems to be related to clinicopathological features known to be relevant in common forms of RCC.
Study Type - Therapy (case series) Level of Evidence4 What's known on the subject? and What does the study add? Unclassified RCC represents 0.7-5.7% of renal tumours. Limited reported data from two series suggests that unclassified RCC is an aggressive form of RCC, mainly because most cases are at an advanced stage at presentation, but overall and cancer-specific survival were not significantly different between unclassified and clear-cell RCC in an additional series of 38 patients. Our study of 56 cases of unclassified RCC describes the pathological features that can be applied to predict prognosis on a daily basis. In particular nuclear grade, TNM classification, tumour coagulative necrosis, tumour size, microvascular invasion and 2004 WHO histotype are independent predictors of disease-free and cancer-specific survival. OBJECTIVE * To evaluate the clinicopathological features and outcomes of 56 patients with unclassified renal cell carcinoma (RCC) meeting 2004 World Health Organization diagnostic criteria. PATIENTS AND METHODS * Urological pathology files of the participating institutions were reviewed and cases of unclassified RCC that met the inclusion criteria were retrieved. * Nuclear grade, pT status, tumour size, regional lymph node involvement, distant metastases, coagulative tumour necrosis, mucin and sarcomatoid differentiation were evaluated in radical nephrectomy or nephron-sparing specimens. * Significant factors in univariate analysis were then assessed by a multivariate analysis of independent prognostic factors using Cox proportional hazard regression analysis. RESULTS * Fifty-six cases met the histological criteria for unclassified RCC. Thirty-four (61%) cases were categorized as unrecognizable cell type (mean overall survival 47 months; median 36 months), 20 (36%) as composites of recognized types (mean overall survival 36 months; median 26 months), and two (4%) (mean survival 16 months; median 16 months) as pure sarcomatoid morphology without recognizable epithelial elements. * Cox multivariate analysis showed nuclear grade (P= 0.020), stage (P < 0.001), tumour coagulative necrosis (P= 0.018), tumour size (P < 0.001), microvascular invasion (P < 0.001) and tumour histotype (P= 0.028) to be independent predictors of disease-free survival, with tumour size being the most significant (hazard ratio [HR] 9.068, 95% confidence interval [CI] 3.231-25.453). * Nuclear grade (P= 0.026), stage (P < 0.001), tumour coagulative necrosis (P < 0.001), tumour size (P= 0.044), microvascular invasion (P < 0.001), tumour recurrence after surgery (P < 0.001) and tumour histotype (P= 0.056) were independent predictors of cancer-specific survival, with tumour recurrence after surgery being the most significant (HR 14.713, 95% CI 5.329-40.622). CONCLUSION * The prognosis of patients with unclassified RCC seems to be related to clinicopathological features known to be relevant in common forms of RCC. [PUBLICATION ABSTRACT]
Author Blanca, Ana
Hartmann, Arndt
Algaba, Ferran
Montironi, Rodolfo
Scarpelli, Marina
Lopez‐Beltran, Antonio
Kirkali, Ziya
Yorukoglu, Kutsal
Cheng, Liang
Author_xml – sequence: 1
  givenname: Antonio
  surname: Lopez‐Beltran
  fullname: Lopez‐Beltran, Antonio
– sequence: 2
  givenname: Ziya
  surname: Kirkali
  fullname: Kirkali, Ziya
– sequence: 3
  givenname: Rodolfo
  surname: Montironi
  fullname: Montironi, Rodolfo
– sequence: 4
  givenname: Ana
  surname: Blanca
  fullname: Blanca, Ana
– sequence: 5
  givenname: Ferran
  surname: Algaba
  fullname: Algaba, Ferran
– sequence: 6
  givenname: Marina
  surname: Scarpelli
  fullname: Scarpelli, Marina
– sequence: 7
  givenname: Kutsal
  surname: Yorukoglu
  fullname: Yorukoglu, Kutsal
– sequence: 8
  givenname: Arndt
  surname: Hartmann
  fullname: Hartmann, Arndt
– sequence: 9
  givenname: Liang
  surname: Cheng
  fullname: Cheng, Liang
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26318438$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22404824$$D View this record in MEDLINE/PubMed
BookMark eNqNkF1r2zAUhsVoWT-2vzAMY7CbePo4lu1dDLqydiuF3izQO3FiS6CgSJlk0-TfT27SDrINqgtJnPO8R3rfM3Lkg9eEFIyWLK9Py5KBhBkwel9yynjJaCug3Lwip8-No6c7beUJOUtpSWkuyOo1OeEcKDQcTkk9953DlKyxui-i9uiKTru8YeysDyv8XGCur0McimCKSuZO0ukNOTbokn67P8_J_Orbz8vvs9u76x-XF7ezrgKAmWzRNIxTMI0E1ooFyNpA1VZUirpCRGpqBhzFgrUMqOALymnf17xvGRNIxTlpd3NHv8btAzqn1tGuMG4Vo2oKQy3V5FNlzxs1haEew1CbrP24065j-DXqNKiVTZM59DqMaVKDbGVdTc-8P0CXYYw5jEyJSgjJBK8z9W5PjYuV7p9_8hRnBj7sAUwdOhPRdzb94aRgDYgmc192XBdDSlEb1dkBBxv8ENG6f1i7P7TWHAz4fyp_SfdvP1inty_Wqa8388er-A27XLgg
CODEN BJINFO
CitedBy_id crossref_primary_10_1016_j_jasc_2024_11_002
crossref_primary_10_4103_iju_iju_256_24
crossref_primary_10_5858_arpa_2013_0653_RA
crossref_primary_10_1016_j_abb_2020_108623
crossref_primary_10_4143_crt_2018_671
crossref_primary_10_1016_j_humpath_2020_06_007
crossref_primary_10_1097_MD_0000000000028380
crossref_primary_10_1097_PAP_0000000000000341
crossref_primary_10_1097_PCR_0000000000000215
crossref_primary_10_1097_PAS_0000000000001629
crossref_primary_10_1016_j_ctrv_2015_05_006
crossref_primary_10_1111_his_13362
crossref_primary_10_3892_mco_2016_900
crossref_primary_10_1016_j_path_2015_09_003
crossref_primary_10_1111_iju_14648
crossref_primary_10_3390_ijms24097946
crossref_primary_10_17650_1726_9776_2019_15_3_126_131
crossref_primary_10_3390_medicina59101845
crossref_primary_10_4111_kju_2014_55_10_690
crossref_primary_10_1016_j_clgc_2016_12_019
crossref_primary_10_1016_j_ajur_2024_02_005
crossref_primary_10_1016_j_hpr_2022_300611
crossref_primary_10_1038_s41598_019_52059_y
Cites_doi 10.1016/j.eururo.2010.08.001
10.1309/AJCPPPR57HNJMSLZ
10.1016/j.juro.2010.12.037
10.1111/j.1464-410X.2008.07999.x
10.1016/j.juro.2007.09.076
10.1097/01.pas.0000131558.32412.40
10.1016/j.juro.2007.03.128
10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
10.1097/01.pai.0000213144.70148.8e
10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R
10.1016/S0022-5347(05)64549-1
10.5858/2007-131-1234-RDAEEO
10.1159/000020370
10.1053/j.semdp.2008.07.006
10.1111/j.1442-2042.2009.02302.x
10.1111/j.1464-410X.2007.07148.x
10.1097/01.cad.0000390767.85658.83
10.1016/j.eururo.2005.11.035
10.1053/j.seminoncol.2006.06.009
10.1016/j.urology.2009.12.037
ContentType Journal Article
Copyright 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL
2015 INIST-CNRS
2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
Copyright_xml – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL
– notice: 2015 INIST-CNRS
– notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
ADTOC
UNPAY
DOI 10.1111/j.1464-410X.2012.10934.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Calcium & Calcified Tissue Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1464-410X
EndPage 793
ExternalDocumentID 10.1111/j.1464-410x.2012.10934.x
2975496401
22404824
26318438
10_1111_j_1464_410X_2012_10934_x
BJU10934
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
1OB
ADTOC
UNPAY
ID FETCH-LOGICAL-c5444-69af81204f864193b467f459506375aaa0f7142a3b1914032b020dd72d9113a03
IEDL.DBID UNPAY
ISSN 1464-4096
1464-410X
IngestDate Tue Aug 19 19:57:48 EDT 2025
Thu Oct 02 05:30:27 EDT 2025
Tue Oct 07 06:15:21 EDT 2025
Mon Jul 21 06:02:19 EDT 2025
Mon Jul 21 09:17:19 EDT 2025
Wed Oct 01 04:28:53 EDT 2025
Thu Apr 24 22:50:52 EDT 2025
Wed Jan 22 16:52:58 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Kidney disease
Nephrology
unclassified
Urinary system disease
Carcinoma
Prognosis
pathology
Malignant tumor
Survival
Urology
Case study
Anatomic pathology
renal cell carcinoma
Kidney cancer
Classification
Grawitz tumor
WHO classification
Cancer
WHO
Language English
License CC BY 4.0
2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5444-69af81204f864193b467f459506375aaa0f7142a3b1914032b020dd72d9113a03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2012.10934.x
PMID 22404824
PQID 1353361327
PQPubID 1026371
PageCount 8
ParticipantIDs unpaywall_primary_10_1111_j_1464_410x_2012_10934_x
proquest_miscellaneous_1114696750
proquest_journals_1353361327
pubmed_primary_22404824
pascalfrancis_primary_26318438
crossref_citationtrail_10_1111_j_1464_410X_2012_10934_x
crossref_primary_10_1111_j_1464_410X_2012_10934_x
wiley_primary_10_1111_j_1464_410X_2012_10934_x_BJU10934
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2012
PublicationDateYYYYMMDD 2012-09-01
PublicationDate_xml – month: 09
  year: 2012
  text: September 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
– name: Edgecliff
PublicationTitle BJU international
PublicationTitleAlternate BJU Int
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Wiley-Blackwell
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley-Blackwell
– name: Wiley Subscription Services, Inc
References 1997; 80
2010; 76
2007; 178
2010; 58
2000; 38
1997; 183
2011
2006; 33
2004; 28
2002; 168
2006; 49
2007; 100
2010; 134
2007; 131
2008; 25
2011; 22
2004
2008; 179
2008; 102
2011; 185
2009; 16
2007; 15
e_1_2_8_18_2
e_1_2_8_19_2
e_1_2_8_12_2
e_1_2_8_23_2
e_1_2_8_13_2
e_1_2_8_14_2
e_1_2_8_15_2
e_1_2_8_9_2
Shen SS (e_1_2_8_16_2) 2007; 131
e_1_2_8_2_2
e_1_2_8_3_2
Eble JN (e_1_2_8_4_2) 2004
e_1_2_8_6_2
e_1_2_8_5_2
e_1_2_8_8_2
e_1_2_8_7_2
e_1_2_8_20_2
e_1_2_8_10_2
e_1_2_8_21_2
e_1_2_8_11_2
e_1_2_8_22_2
Algaba F (e_1_2_8_17_2) 2011
References_xml – volume: 80
  start-page: 987
  year: 1997
  end-page: 9
  article-title: Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)
  publication-title: Cancer
– year: 2011
– volume: 178
  start-page: 425
  year: 2007
  end-page: 8
  article-title: Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma
  publication-title: J Urol
– volume: 16
  start-page: 432
  year: 2009
  end-page: 43
  article-title: 2009 update on the classification of renal epithelial tumors in adults
  publication-title: Int J Urol
– volume: 185
  start-page: 1611
  year: 2011
  end-page: 4
  article-title: Prognostic factors for renal cell carcinoma with bone metastasis: who are the long‐term survivors?
  publication-title: J Urol
– volume: 102
  start-page: 1381
  year: 2008
  end-page: 4
  article-title: Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC
  publication-title: BJU Int
– volume: 183
  start-page: 131
  year: 1997
  end-page: 3
  article-title: The Heidelberg classification of renal cell tumours
  publication-title: J Pathol
– volume: 58
  start-page: 655
  year: 2010
  end-page: 68
  article-title: Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors
  publication-title: Eur Urol
– volume: 38
  start-page: 728
  year: 2000
  end-page: 33
  article-title: Prognostic significance of microvascular invasion in localized renal cell carcinoma
  publication-title: Eur Urol
– volume: 15
  start-page: 310
  year: 2007
  end-page: 5
  article-title: Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications
  publication-title: Appl Immunohistochem Mol Morphol
– year: 2004
– volume: 168
  start-page: 950
  year: 2002
  end-page: 5
  article-title: Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype
  publication-title: J Urol
– volume: 33
  start-page: 534
  year: 2006
  end-page: 43
  article-title: The pathology of renal epithelial neoplasms
  publication-title: Semin Oncol
– volume: 49
  start-page: 798
  year: 2006
  end-page: 805
  article-title: 2004 WHO classification of the renal tumors of the adults
  publication-title: Eur Urol
– volume: 76
  start-page: 580
  year: 2010
  end-page: 6
  article-title: Unclassified renal cell carcinoma: impact on survival following nephrectomy
  publication-title: Urology
– volume: 131
  start-page: 1234
  year: 2007
  end-page: 43
  article-title: Recently Described and Emphasized Entities of Renal Neoplasms
  publication-title: Arch Pathol Lab Med
– volume: 28
  start-page: 1117
  year: 2004
  end-page: 32
  article-title: Morphologic and molecular characterization of renal cell carcinoma in children and young adults
  publication-title: Am J Surg Pathol
– volume: 134
  start-page: 873
  year: 2010
  end-page: 9
  article-title: Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade
  publication-title: Am J Clin Pathol
– volume: 25
  start-page: 232
  year: 2008
  end-page: 44
  article-title: Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications
  publication-title: Semin Diagn Pathol
– volume: 100
  start-page: 802
  year: 2007
  end-page: 8
  article-title: Unclassified renal cell carcinoma: an analysis of 85 cases
  publication-title: BJU Int
– volume: 22
  start-page: S9
  issue: 1
  year: 2011
  end-page: S14
  article-title: Non‐clear cell advanced kidney cancer: is there a gold standard?
  publication-title: Anticancer Drugs
– volume: 179
  start-page: 439
  year: 2008
  end-page: 43
  article-title: The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification
  publication-title: J Urol
– ident: e_1_2_8_18_2
  doi: 10.1016/j.eururo.2010.08.001
– ident: e_1_2_8_22_2
  doi: 10.1309/AJCPPPR57HNJMSLZ
– ident: e_1_2_8_14_2
  doi: 10.1016/j.juro.2010.12.037
– ident: e_1_2_8_23_2
  doi: 10.1111/j.1464-410X.2008.07999.x
– volume-title: Pathology and Genetics. Tumors of the Urinary System and Male Genital Organs
  year: 2004
  ident: e_1_2_8_4_2
– ident: e_1_2_8_6_2
  doi: 10.1016/j.juro.2007.09.076
– ident: e_1_2_8_11_2
  doi: 10.1097/01.pas.0000131558.32412.40
– ident: e_1_2_8_20_2
  doi: 10.1016/j.juro.2007.03.128
– ident: e_1_2_8_2_2
  doi: 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
– ident: e_1_2_8_10_2
  doi: 10.1097/01.pai.0000213144.70148.8e
– ident: e_1_2_8_3_2
  doi: 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R
– ident: e_1_2_8_7_2
  doi: 10.1016/S0022-5347(05)64549-1
– volume: 131
  start-page: 1234
  year: 2007
  ident: e_1_2_8_16_2
  article-title: Recently Described and Emphasized Entities of Renal Neoplasms
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/2007-131-1234-RDAEEO
– volume-title: ICUD‐EAU International Consultation on Kidney Cancer 2011: Pathology
  year: 2011
  ident: e_1_2_8_17_2
– ident: e_1_2_8_19_2
  doi: 10.1159/000020370
– ident: e_1_2_8_12_2
  doi: 10.1053/j.semdp.2008.07.006
– ident: e_1_2_8_13_2
  doi: 10.1111/j.1442-2042.2009.02302.x
– ident: e_1_2_8_8_2
  doi: 10.1111/j.1464-410X.2007.07148.x
– ident: e_1_2_8_21_2
  doi: 10.1097/01.cad.0000390767.85658.83
– ident: e_1_2_8_9_2
  doi: 10.1016/j.eururo.2005.11.035
– ident: e_1_2_8_5_2
  doi: 10.1053/j.seminoncol.2006.06.009
– ident: e_1_2_8_15_2
  doi: 10.1016/j.urology.2009.12.037
SSID ssj0014665
Score 2.2228117
Snippet Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Unclassified RCC represents 0.7–5.7% of renal...
What's known on the subject? and What does the study add? Unclassified RCC represents 0.7-5.7% of renal tumours. Limited reported data from two series suggests...
Study Type - Therapy (case series) Level of Evidence4 What's known on the subject? and What does the study add? Unclassified RCC represents 0.7-5.7% of renal...
SourceID unpaywall
proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 786
SubjectTerms Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoma, Renal Cell - classification
Carcinoma, Renal Cell - pathology
Confidence intervals
Female
Humans
Kidney Neoplasms - classification
Kidney Neoplasms - pathology
Kidneys
Male
Medical research
Medical sciences
Middle Aged
Multivariate analysis
Nephrology. Urinary tract diseases
pathology
prognosis
renal cell carcinoma
Retrospective Studies
survival
Tumors of the urinary system
unclassified
WHO classification
SummonAdditionalLinks – databaseName: Wiley Online Library - Core collection (SURFmarket)
  dbid: DR2
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9wwDBejD_tgrPtutq5ksNcc-VDsZG_baCmF7mHs4N6M7Yth9Jo7mjvW7a-vZOcycpRRxiAPIbYSW5bsn2xFAvhQ1SJzJAmJrRuTIBYmqYwQSVnZ1MqsKYXfzDn_Kk6neDYrZ73_E_8LE-JDDBturBl-vmYF16bbVXJMMEtn7KGV-8BIOGE8mRXCW1ffhkhSVNVnlQwkBNvHTj23vmi0Uj1e6Y6Y5kK2i9vg6CN4sGlX-tdPvViMka5fqk724WLbyeChcjHZrM3E_t6J__h_uPAUnvSINv4URPAZ3Gva53D_vD-zfwFy2lqG6D8cod34quHKfFwQW05j1C4v9cdYx-HsIl66uBRU0jXdS5ieHH__cpr06RoSWyJiImrtCC6k6CqBhAsNzcEOy7okFCRLrXXqZIa5LgzHlEuL3BBUnc9lPqcJt9Bp8Qr22mXbHEBcabLbtBCOg8ejNbWWdDk0tq4biXUEcjs0yvaxzDmlxkKNbBpUzBfFfFGeL-o6gmygXIV4HnegORqN_kCYi4LT5VQRHG7FQfVTQKc4oUhBYCmXEbwfikl5mcW6bZabjj-LoiabLY3gdRCjPy8nrIVVjhHkg1z9pcnXO02WXmru3Ef1-Wzqb9_8M-VbeMjPgwPeIeytrzbNO0Jsa3PkdfEGvrIpgA
  priority: 102
  providerName: Wiley-Blackwell
Title Unclassified renal cell carcinoma: a report of 56 cases
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2012.10934.x
https://www.ncbi.nlm.nih.gov/pubmed/22404824
https://www.proquest.com/docview/1353361327
https://www.proquest.com/docview/1114696750
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2012.10934.x
UnpaywallVersion publishedVersion
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1464-410X
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0014665
  issn: 1464-410X
  databaseCode: ABDBF
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1464-410X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014665
  issn: 1464-410X
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1464-410X
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1464-410X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0014665
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ri9QwEB-OPfCB-H5Uz6WCX7u26TRp_HaKx3Fwi4iF9VNJsg2Ia7tcd3H1r3fSdKs9RA4R-iFt3tPJ5JdkMgPwMpc8scQJkZGVjhBTHeWa8yjLTWxEUmW828w5n_PTAs8W2eIA5vu7MN4-xLDh5kZGJ6_dAF8vrZfzr37Tx0GOESbxwmlpsc44Es4IUx7yjLD5BA6L-fvjT_6KESWMJR_ClGms2tN_3Y2KGs1Xt9aqJdJZ7_PiT6D0Jlzf1mv1_ZtarcZ4t5uwTu5As--q11P5Mttu9Mz8uGQF8v_R4i7c7rFteOyZ8R4cVPV9uHben94_AFHUxoH1z5Zwb3hRucTu4CA0zqFR3XxVr0MV-lOMsLFhximmrdqHUJy8-_j2NOodN0QmQ8SIS2UJOMRoc46EEDVJY4uZzAgPiUwpFVuRIFOpdtbl4pRpAq3LpWBLEr2pitNHMKmbunoCYa5oBac4t86MPBotlaDHojZSVgJlAGL_e0rTWzV3zjVW5Wh1g6WjS-noUnZ0KXcBJEPOtbfscYU80xEHDBkZT53jnDyAoz1LlL0waEvnWiQl2MREAC-GaBrGjsSqrppt66pFLmn1Fgfw2LPSr8IJdWHOMAA28NZfmry71GTRcc6V-1i-OSu64NN_qe4Z3HCvXgvvCCabi231nGDbRk9pwfKBTfsR-RNrVy8_
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_kBE8Rvz-q51nB1y79mCaNb34d63l7D3IL-xaSbAPi2l2uu3j61zvTditdDjlE6ENpMm0ymZn8kkxnAF4XSiSeJCFyqrQRYmajwgoR5YWLnUzKXDSbOZNTMZ7i8SyfdemA-F-YNj5Ev-HGmtHYa1Zw3pDe1XKMMIln7KKVNpGRcESA8jo9j1nEP3zpY0lR3SavZEtDwH3o1nPpmwZz1e2VqYltvs13cRkgvQX7m2plfv4wi8UQ6zaT1dFdWGy72fqofBtt1nbkfu1EgPxPfLgHdzpQG75tpfA-XCurB3Bj0h3bPwQ5rRyj9K-eAG94XnJlPjEIHWcyqpbfzZvQhO3xRbj0YS6opC7rRzA9-nj2fhx1GRsilyNiJJTxhBhi9IVAgoaWzLDHXOUEhGRujIm9TDA1meWwcnGWWkKr87lM52RzMxNnj2GvWlblUwgLQ0s3I4Tn-PHorDKSLo_WKVVKVAHI7dho14Uz56waCz1Y1qBmvmjmi274oi8CSHrKVRvS4wo0h4Ph7wlTkXHGnCKAg6086M4K1JpzimSEl1IZwKu-mPSXWWyqcrmp-bMoFC3b4gCetHL05-UEt7BIMYC0F6y_NPlip8myEZsr91G_O542t8_-mfIl7I_PJif65NPp5-dwk-u0_ngHsLc-35QvCMCt7WGjmL8Bg4wtoQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_khNND_D6tnmcFX7v0Y5q0vqnncp7eIeLCvoUkm4C4dpfrLp7-9c603UqXQw4R-lBIJk0mM5NfkukMwMuiFIknSYhs6UyEmJmoMEJEeWFjKxOXi-Yw5_RMHE_wZJpPu3RA_C9MGx-iP3BjzWjsNSu4W878tpZjhEk8ZRettImMhCMClNcxLwv27zv63MeSorpNXsmWhoD70K3n0pYGa9Wtpa6Jbb7Nd3EZIN2DG-tqqX_-0PP5EOs2i9X4Dsw3w2x9VL6N1iszsr-2IkD-Jz7chdsdqA1ft1J4D6656j7snnbX9g9ATirLKP2rJ8AbnjuuzDcGoeVMRtXiu34V6rC9vggXPswFldSufgiT8bsvb4-jLmNDZHNEjESpPSGGGH0hkKChITPsaTJyAkIy11rHXiaY6sxwWLk4Sw2h1dlMpjOyuZmOs33YqRaVewxhoWnrpoXwHD8erSm1pMejsWXpJJYByM3cKNuFM-esGnM12NagYr4o5otq-KIuAkh6ymUb0uMKNIeD6e8JU5FxxpwigIONPKjOCtSKc4pkhJdSGcCLvpj0l1msK7dY1_xZFCVt2-IAHrVy9KdxgltYpBhA2gvWX7p8sdVl2YjNlceo3pxMmtcn_0z5HHY_HY3Vx_dnH57CTa7SuuMdwM7qfO2eEX5bmcNGL38D6jktJQ
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB-OPVAP8fujeh4VfO3aj2nS-HaKx3Fwiw8W1qeQZBs4XNvlusut_vVOmm61h8ghQh_S5ns6mfySTGYA3hSCJZY4ITKi0hFipqNCMxblhYkNT6qcdZs55zN2WuLZPJ_vwWx3F8bbhxg23NzI6OS1G-CrhfVy_u1v-jjIMMIknjstrbQzjoRTwpT7LCdsPoH9cvbp-Iu_YkQJY8GGMGUaq_b0X7ejokbz1d2Vaol01vu8-BMoPYDbm3qlvl-p5XKMd7sJ6-Q-NLuuej2Vr9PNWk_Nj2tWIP8fLR7AvR7bhseeGR_CXlU_glvn_en9Y-BlbRxYv7CEe8PLyiV2BwehcQ6N6uabeheq0J9ihI0Nc0YxbdU-gfLk4-cPp1HvuCEyOSJGTChLwCFGWzAkhKhJGlvMRU54iOdKqdjyBFOVaWddLs5STaB1seDpgkRvpuLsKUzqpq6eQ1goWsEpxqwzI49GC8XpsaiNEBVHEQDf_R5peqvmzrnGUo5WNygdXaSji-zoIrcBJEPOlbfscYM8RyMOGDKmLHOOc4oADncsIXth0ErnWiQj2JTyAF4P0TSMHYlVXTWb1lWLTNDqLQ7gmWelX4UT6sIixQDSgbf-0uTttSbzjnNu3Ef5_qzsgi_-pbqXcMe9ei28Q5isLzfVK4Jta33Uj8WfVbouVg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Unclassified+renal+cell+carcinoma%3A+a+report+of+56+cases&rft.jtitle=BJU+international&rft.au=LOPEZ-BELTRAN%2C+Antonio&rft.au=KIRKALI%2C+Ziya&rft.au=MONTIRONI%2C+Rodolfo&rft.au=BLANCA%2C+Ana&rft.date=2012-09-01&rft.pub=Wiley-Blackwell&rft.issn=1464-4096&rft.volume=110&rft.issue=6&rft.spage=786&rft.epage=793&rft_id=info:doi/10.1111%2Fj.1464-410X.2012.10934.x&rft.externalDBID=n%2Fa&rft.externalDocID=26318438
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon